|
gptkbp:instanceOf
|
gptkb:drug
synthetic peptide
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:H01CB02
|
|
gptkbp:brand
|
gptkb:Sandostatin
|
|
gptkbp:CASNumber
|
83150-76-9
|
|
gptkbp:developedBy
|
1980s
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
1.5 hours (subcutaneous)
22 hours (long-acting)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasEnantiomer
|
gptkb:L-octreotide
|
|
gptkbp:hasMolecularFormula
|
C49H66N10O10S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
octreotide
|
|
gptkbp:KEGGID
|
D00436
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
somatostatin analog
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
Category B (US)
|
|
gptkbp:proteinBinding
|
65%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
395264
448601
DB00104
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
subcutaneous injection
intravenous injection
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
bradycardia
hyperglycemia
gallstones
|
|
gptkbp:UNII
|
T9D2J32KEF
|
|
gptkbp:usedFor
|
gptkb:carcinoid_syndrome
acromegaly
bleeding esophageal varices
vasoactive intestinal peptide-secreting tumors
|
|
gptkbp:bfsParent
|
gptkb:Sandostatin
|
|
gptkbp:bfsLayer
|
5
|